The aim of Thursday’s meeting was to “determine if we’ve reached a point in the pandemic where we can simplify and take a more routine approach,” said Dr. David Kaslow, director of the Office of Vaccines Research and Review at the FDA.
Advertisment
The aim of Thursday’s meeting was to “determine if we’ve reached a point in the pandemic where we can simplify and take a more routine approach,” said Dr. David Kaslow, director of the Office of Vaccines Research and Review at the FDA.